Article
Oncology
Benedetto Neri, Maria Lia Scribano, Alessandro Armuzzi, Fabiana Castiglione, Renata D'Inca, Ambrogio Orlando, Stefano Festa, Gabriele Riegler, Walter Fries, Gianmichele Meucci, Patrizia Alvisi, Filippo Mocciaro, Claudio Papi, Michelangela Mossa, Giorgia Sena, Luisa Guidi, Anna Testa, Sara Renna, Iris Frankovic, Anna Viola, Marta Patturelli, Carlo Chiaramonte, Livia Biancone
Summary: The sequence chronic inflammation-dysplasia-cancer is involved in the development of several gastrointestinal cancers. The characteristics of IBD, including CRC-related symptoms at onset, play a role in the long-term outcome of CRC in IBD patients. CRC has a higher incidence in UC and CD patients. Surveillance programs should focus on high-risk subgroups of patients.
Review
Gastroenterology & Hepatology
Ana Elisa Valencise Quaglio, Thais Gagno Grillo, Ellen Cristina Souza De Oliveira, Luiz Claudio Di Stasi, Ligia Yukie Sassaki
Summary: Dysbiosis in the gut microbiota is closely associated with various gastrointestinal disorders such as IBS, IBD, and CRC, potentially leading to mucosal barrier disruption, chronic inflammation, and cancer progression. Specific harmful bacteria, like E. coli and ETBF, are linked to an increased risk of developing CRC.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Lifang Liang, Rongxiao Lin, Ying Xie, Huaqing Lin, Fangyuan Shao, Wen Rui, Hongyuan Chen
Summary: This review briefly summarizes the expression of CypA, CypB, and CypD in IBD and CRC, their relationship with the development of these two intestinal diseases, as well as the possible pathogenesis, providing a modest reference for future clinical research and treatments.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Kristiina Rajamaki, Aurora Taira, Riku Katainen, Niko Valimaki, Anna Kuosmanen, Roosa-Maria Plaketti, Toni T. Seppala, Maarit Ahtiainen, Erkki-Ville Wirta, Emilia Vartiainen, Paivi Sulo, Janne Ravantti, Suvi Lehtipuro, Kirsi J. Granberg, Matti Nykter, Tomas Tanskanen, Ari Ristimaki, Selja Koskensalo, Laura Renkonen-Sinisalo, Anna Lepisto, Jan Bohm, Jussi Taipale, Jukka-Pekka Mecklin, Mervi Aavikko, Kimmo Palin, Lauri A. Aaltonen
Summary: By comprehensively characterizing IBD-associated tumorigenesis using multiple high-throughput approaches, distinct mechanisms of WNT pathway dysregulation were identified in IBD-CRC, which skew the tumors towards a mesenchymal subtype. Additionally, epigenetic modifications and noncoding mutations in specific genes were found in IBD-CRC, highlighting further differences compared to sCRC.
Review
Endocrinology & Metabolism
Yuxuan Xia, Li Zhang, Dickson Kofi Wiredu Ocansey, Qiang Tu, Fei Mao, Xiumei Sheng
Summary: Inflammatory bowel disease (IBD) and colorectal cancer (CRC) share a common factor in their development, glycolysis, which affects various aspects of gastrointestinal tissues. In IBD, glycolysis impacts the intestinal microbiota, mucosal barrier function, and the immune system, while in CRC, it is linked to multiple signaling pathways and transcription factors. A comprehensive study of glycolysis is crucial for a better understanding of the pathogenesis and therapeutic targets of both IBD and CRC.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Oncology
Elisa Marabotto, Stefano Kayali, Silvia Buccilli, Francesca Levo, Giorgia Bodini, Edoardo G. Giannini, Vincenzo Savarino, Edoardo Vincenzo Savarino
Summary: This review summarizes the current epidemiology, risk factors, and prevention strategies for colorectal cancer (CRC) in patients with inflammatory bowel diseases (IBDs). It focuses on the importance of chemoprevention and endoscopic surveillance as proposed by international scientific societies. Unresolved research and clinical problems related to this topic are also highlighted to improve diagnostic strategies and management.
Review
Oncology
Mostafa Vaghari-Tabari, Niloufar Targhazeh, Soheila Moein, Durdi Qujeq, Forough Alemi, Maryam Majidina, Simin Younesi, Zatollah Asemi, Bahman Yousefi
Summary: Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease with relapse and remission periods, and it increases the risk of colorectal cancer, especially in patients with Ulcerative colitis. The importance of miRNAs in the pathophysiology of IBD and colorectal cancer has been recognized, and they may be potential therapeutic targets.
CANCER CELL INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Shailja C. Shah, Steven H. Itzkowitz
Summary: Patients with inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer (CRC). Chronic inflammation plays a key role in the development of neoplastic progression, resulting in dysplastic precursor lesions. Colitis-associated CRC shares molecular similarities with sporadic CRC and the microbiome and host immune system may also play a role. However, further research is needed to understand the specific molecular differences and their role in inflammation-associated cancers.
Review
Biochemistry & Molecular Biology
Letizia Masi, Ivan Capobianco, Carlotta Magri, Irene Marafini, Valentina Petito, Franco Scaldaferri
Summary: Inflammatory bowel disease (IBD) is a chronic relapsing autoimmune disease, and miRNAs have the potential to serve as important biomarkers in diagnosis and treatment, as well as for developing a new screening model for colorectal cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Thais Gagno Grillo, Ana Elisa Valencise Quaglio, Rodrigo Fedatto Beraldo, Talles Bazeia Lima, Julio Pinheiro Baima, Luiz Claudio Di Stasi, Ligia Yukie Sassaki
Summary: miRNAs play a crucial role in regulating gene expression and immune-mediated disorders, particularly in the diagnosis and prognosis of CRC associated with IBD.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Article
Pediatrics
Min Jee Kim, Jae Sung Ko, Minsoo Shin, Jong Woo Hahn, Soo Young Moon, Hyun Young Kim, Jin Soo Moon
Summary: This study found that pediatric-onset CRC patients were diagnosed at a younger age and had a shorter period of CRC development compared to adult-onset CRC patients. The majority of CRC cases occurred in the sigmoid colon, with adenocarcinoma being the most common histological type.
Article
Gastroenterology & Hepatology
Miles W. Grunvald, Joshua M. Underhill, Nicholas J. Skertich, Michael D. Williams, Christopher T. Aquina, Anuradha R. Bhama, Dana M. Hayden, Adan Z. Becerra
Summary: This study found that there are racial disparities in treatment delay among colorectal cancer patients, with minority patients experiencing longer treatment times. Income, education, comorbidities, insurance, and hospital type were important factors contributing to these disparities. Treatment delays could be significantly reduced if these factors were equalized to that of white patients.
DISEASES OF THE COLON & RECTUM
(2023)
Review
Pharmacology & Pharmacy
Mengjiao Zhou, Danfeng Wang, Xiang Li, Ying Cao, Chengxue Yi, Dickson Kofi Wiredu Ocansey, Yuling Zhou, Fei Mao
Summary: FXR, a nuclear receptor activated by bile acids, plays a vital role in bile acid metabolism and immune cell function. It affects the response of immune cells to changes in bile acids by regulating immune cell function and chemokine release. In addition to ligand regulation, FXR is also controlled by post-translational modification activities. With its high expression in the liver and intestine, FXR significantly influences intestinal homeostasis through enterohepatic circulation, protecting the intestinal barrier, resisting bacterial infection, reducing oxidative stress, inhibiting inflammatory reactions, and impairing the multiplication and invasion of tumor cells. It has potential applications in the treatment of inflammatory bowel disease and colorectal cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Brigida Barberio, Edoardo Savarino, Bram Verstockt, Mathurin Fumery, Daniela Pugliese, Lorenzo Bertani, Andrea Buda, Gabriele Dragoni, Idan Goren, Ido Laish, Antonino Spinelli, Niels Teich, Marie Truyens, Pierre Ellul
Summary: This is the largest case series of patients with IBD and HCCS to date, and Lynch syndrome was the most common diagnosis of HCCS associated with IBD. Despite endoscopic surveillance, these IBD patients had a high rate of malignant tumor development and surgical intervention.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Estefania Flores, Chimezie Mbachi, Ikechukwu Achebe, Jennifer Asotibe, Emmanuel Palomera-Tejeda, Ishaan Vohra, Victor Udechukwu, Vikram Kotwal
Summary: While mortality trends in non-IBD-CRC population have significantly decreased, there is no significant trend in mortality for IBD-CRC population. Further strategies are needed to reduce IBD-CRC mortality trends.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)